Celularity Inc.

NasdaqCM:CELU Stock Report

Market Cap: US$22.2m

Celularity Past Earnings Performance

Past criteria checks 0/6

Celularity has been growing earnings at an average annual rate of 14.5%, while the Biotechs industry saw earnings growing at 30.5% annually. Revenues have been growing at an average rate of 24.3% per year.

Key information

14.50%

Earnings growth rate

76.95%

EPS growth rate

Biotechs Industry Growth17.04%
Revenue growth rate24.34%
Return on equityn/a
Net Margin-345.28%
Last Earnings Update31 Dec 2025

Recent past performance updates

Recent updates

Analysis Article • Dec 15

There Is A Reason Celularity Inc.'s (NASDAQ:CELU) Price Is Undemanding

With a price-to-sales (or "P/S") ratio of 1.1x Celularity Inc. ( NASDAQ:CELU ) may be sending very bullish signals at...
Analysis Article • Aug 14

Celularity Inc. (NASDAQ:CELU) Held Back By Insufficient Growth Even After Shares Climb 59%

NasdaqCM:CELU 1 Year Share Price vs Fair Value Explore Celularity's Fair Values from the Community and select yours...
Analysis Article • Feb 21

Celularity Inc.'s (NASDAQ:CELU) Business And Shares Still Trailing The Industry

You may think that with a price-to-sales (or "P/S") ratio of 0.8x Celularity Inc. ( NASDAQ:CELU ) is definitely a stock...
Analysis Article • Feb 14

Celularity Inc. (NASDAQ:CELU) Held Back By Insufficient Growth Even After Shares Climb 80%

The Celularity Inc. ( NASDAQ:CELU ) share price has done very well over the last month, posting an excellent gain of...
Seeking Alpha • Oct 03

Celularity appoints Adrian Kilcoyne as chief medical officer

Celularity (NASDAQ:CELU) said on Monday it had appointed Adrian Kilcoyne as the Executive Vice President, Chief Medical Officer (CMO) and Head of Global Medical Affairs, Patient Safety and Patient Affairs, effective today. "Kilcoyne will play a fundamental role in advancing our clinical pipeline, including our three Phase 1 studies in acute myeloid leukemia, glioblastoma multiforme and gastric cancer, and one IND-pending program in B-cell malignancies," the company said. Kilcoyne has served as the Chief Medical Officer of Humanigen and Vice President of Global Oncology Evidence Generation and External Alliances in AstraZeneca.
Seeking Alpha • Sep 15

Celularity falls after announcing fund raising deal

The shares of Celularity Inc. (NASDAQ:CELU) dropped more than 10% Thursday after the cell therapy company announced an agreement with an affiliate of the investment manager Yorkville Advisors Global to raise as much as $150M. Per the terms of the deal called Pre-Paid Advance Agreement, CELU is entitled to request up to $80M individual pre-paid advances from Yorkville under certain conditions at a 2% discount and an interest rate of 6%. The deal provides up to $150M of total funding over the next 18 months. However, if there is an outstanding balance of a pre-paid advance over the 18 months, CELU will be required to sell shares of its common stock to Yorkville. The company expects to use the proceeds for working capital and other general corporate purposes. The deal comes after CELU announced an agreement last week to sell up to $150M worth of its common stock in an at-the-market offering.
Seeking Alpha • Sep 08

Celularity falls 10% on deal for $150M common stock offering

The shares of Celularity Inc. (NASDAQ:CELU), a biotech focused on cell therapies, fell ~10% on Thursday after the company announced an agreement to sell up to $150M worth of its common stock in an at-the-market offering. Per the terms of the agreement with BTIG, Oppenheimer, and B. Riley Securities, the company, from time to time, will sell shares of its Class A common stock with a par value of $0.0001 per share and an aggregate offering price of up to $150.0M through the sales agents. CELU is not obligated to sell shares under the agreement, and any decision on sales will be dependent on factors such as market conditions and capital needs, the company said. With its Q2 2022 financials, CELU reported $38M of cash and equivalents as of June 30, following a private placement for ~$27.5M in net cash proceeds.
Seeking Alpha • Jul 27

Celularity begins phase 1/2a trial for cell therapy CYNK-101 to treat cancers

Celularity (NASDAQ:CELU) said the first patient had been treated in a phase 1/2a trial with CYNK-101, an investigational genetically modified natural killer (NK) cell therapy to treat cancers. The drug, CYNK-101, was granted both a Fast Track Designation and an Orphan Drug Designation by the U.S. Food and Drug Administration for the treatment of human epidermal growth factor receptor 2 (HER2) positive G/GEJ cancer.

Revenue & Expenses Breakdown

How Celularity makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NasdaqCM:CELU Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 2527-925115
30 Sep 2541-815216
30 Jun 2545-745615
31 Mar 2551-565915
31 Dec 2454-585917
30 Sep 2448-355613
30 Jun 2443-1135415
31 Mar 2434-1545119
31 Dec 2323-1965130
30 Sep 2315-1815742
30 Jun 2315-836157
31 Mar 2316136374
31 Dec 2218146678
30 Sep 2219-145189
30 Jun 2225315892
31 Mar 2225-817190
31 Dec 2121-1006285
30 Sep 2120-926478
30 Jun 2112-1885165
31 Mar 2113-2603058
31 Dec 2014-2083153
30 Sep 2016-2343552
31 Dec 1921-2124246
31 Dec 1818-135029

Quality Earnings: CELU is currently unprofitable.

Growing Profit Margin: CELU is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: CELU is unprofitable, but has reduced losses over the past 5 years at a rate of 14.5% per year.

Accelerating Growth: Unable to compare CELU's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CELU is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (43%).

Return on Equity

High ROE: CELU's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/12 05:21
End of Day Share Price 2026/05/12 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Celularity Inc. is covered by 6 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
James MolloyAlliance Global Partners
Thomas ShraderBTIG
Swayampakula RamakanthH.C. Wainwright & Co.